NCT04382924View on ClinicalTrials.gov

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

December 24, 2020

Study Completion Date

January 26, 2021

Conditions
COVID
Interventions
DRUG

NP-120 (Ifenprodil)

Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID

Trial Locations (10)

3050

Royal Melbourne Hospital, Parkville

4102

Princess Alexandra Hospital, Woolloongabba

33155

Westchester Research Center, Miami

43606

Promedica Health: Toledo Hospital and BayPark Hospital, Toledo

60644

Affinity Health - Loretto Hospital, Chicago

64507

Heartland Regional Medical Center, Saint Joseph

Unknown

Makati Medical Center, Manila

Philippine General Hospital, Manila

Lung Center of the Philippines, Quezon City

021105

National Institute of Infectious Diseases, Bucharest

Sponsors

Collaborators (1)

Novotech (Australia)
All Listed Sponsors
collaborator

Novotech (Australia)

UNKNOWN

lead

Algernon Pharmaceuticals

INDUSTRY

NCT04382924 - Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | Biotech Hunter | Biotech Hunter